Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lucid Diagnostics ( (LUCD) ) has shared an announcement.
On September 10, 2025, Lucid Diagnostics entered into an underwriting agreement for a public offering of its common stock, pricing each share at $1.00. The offering, managed by Canaccord Genuity LLC and BTIG, LLC, aims to raise $25 million, with potential to increase to $28.75 million if additional shares are purchased. The proceeds will support working capital and general corporate purposes, with the sale expected to close on September 11, 2025, subject to customary conditions.
The most recent analyst rating on (LUCD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.
Spark’s Take on LUCD Stock
According to Spark, TipRanks’ AI Analyst, LUCD is a Neutral.
Lucid Diagnostics’ overall stock score is primarily influenced by its financial performance, which is challenged by negative margins and high leverage. The earnings call provides a cautiously optimistic outlook with significant revenue growth and strategic partnerships. However, technical analysis and valuation indicate potential risks, with mixed signals and a negative P/E ratio.
To see Spark’s full report on LUCD stock, click here.
More about Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer. Its EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device are designed for early detection of esophageal precancer.
Average Trading Volume: 1,146,646
Technical Sentiment Signal: Buy
Current Market Cap: $132.9M
See more insights into LUCD stock on TipRanks’ Stock Analysis page.